Intravenous immunoglobulin therapy for severe gastrointestinal involvement in systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 168-170

  Clark, Kristina E N ^a   Etomi, Oseme ^a   Denton, Christopher P ^a   Ong, Voon H ^a   Murray, Charles D ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Gastrointestinal disease; Intravenous immunoglobulin; Myositis; Systemic sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CASE REPORT; DIARRHEA; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYOSITIS; PRIORITY JOURNAL; SATIETY; SWALLOWING; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; CONVALESCENCE; GASTROINTESTINAL DISEASES; IMMUNOLOGY; PATHOPHYSIOLOGY; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MYOSITIS; RECOVERY OF FUNCTION; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84946227555     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. STEEN VD, MEDSGER TA: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
2. FORBES A, MARIE I: Gastrointestinal Complications: the most frequent internal complications of systemic sclerosis. Rheumatology 2008; 48: iii36-iii39.
3. PARODI A, SESSAREGO M, GRECO A et al.: Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 2008; 103: 1257-62.
4. KAYE SA, SEIFALIAN AM, LIM SG, HAMILTON G, BLACK CM: Ischaemia of the small intestine in patients with systemic sclerosis: Raynaud's phenomenon or chronic vasculopathy? Q J Med 1995; 87: 495-500.
5. RUSSELL ML, FRIESEN D, HENDERSON RD, HANNA WM: Ultrastructure of the esophagus in scleroderma. Arthritis Rheum 1982; 25: 117-23.
6. MALDARINI A, SELVI E, VILLANOVA M et al.: Autonomic nervous system and smooth muscle cell involvement in systemic sclerosis: ultrastructural study of 3 cases. J Rheumatol 2000; 27: 1203-6.
7. PAKOZDI A, NIHTYANOVA S, MOINZADEH P, ONG VH, BLACK CM, DENTON CP: Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 2011; 38: 2406-9.
8. DALAKAS MC, ILLA I, DAMBROSIA JM et al.: A Controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2001.
9. CHERIN P, HERSON S, WECHSLER B et al.: Efficacy of intravenousgammaglobulin the-rapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162-8.
10. QUICK A, TANDAN R: Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep 2011; 13: 192-8.
11. THA-IN T, MERSELAAR HJ, TILANUS HW et al.: Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cels. Blood 2007; 110: 3253-65.
12. KAZATCHKINE MD, KAVERI SV: Immuno-modulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.
13. BAYARY J, DASGUPTA S, MISRA N et al.: Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol 2006; 6: 528-34.
14. MANETTI M, GUIDUCCI S, ROMANO E et al.: Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis 2012; 71: 1064-72.
15. GüNTHER J, KILL A, BECKER MO et al.: Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from SSc patients. Arthritis Res Ther 2014; 16: R65.
16. MIESCHER SM, KäSERMANN F: The future of immunoglobulin therapy: An overview of the 2nd international workshop on natural antibodies in health and disease. Autoimmun Rev 2013; 12: 639-42.
17. ROGOSNITZKY M, DANKS R, HOLT D: Intravenous immunoglobulin for the treatment of Crohn's disease. Autoimmun Rev 2012; 12: 275-80,.
18. TAKEHARA K, IHN H, SATO S: A randomized, double-blind, placebo-controlled trial: intra-venous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 2013; 31: 151-6.
19. NACCI F, RIGHI A, CONFORTI ML et al.: Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007; 66: 977-9.
20. MAUHIN W, RIVIERE S, CABANE J et al.: Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis. Scand J Rheumatol 2014; 43: 170-1.